Healio

Gene therapy increases factor VIII activity, reduces bleeding in severe hemophilia A

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...
The American Journal of Managed Care

The Benefits of Sustaining High Factor VIII Levels in People With Hemophilia A

Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...
The New England Journal of Medicine

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5 (AAV5)–based gene-therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-selective promoter.
Nasdaq

Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...